We shall see -- but it could be worth quite a bit more, if the when-, and as-developed oral peptide candidates are able to clear FDA and EU regulatory hurdles (Merck would then pay up for an exclusive, obviously). Here's the presser, from Innsbruck:
. . .Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that the companies have signed a Non-Exclusive License and Option Agreement to develop oral formulations of MSD’s peptides using Cyprumed’s innovative drug delivery technology.
Under the terms of the agreement, MSD gains non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets. The agreement also grants MSD the option to exclusively license Cyprumed’s technology for use with individual targets. Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the collaboration.
Cyprumed may receive additional payments if MSD exercises its Exclusive License Option. . . .
Now you know -- with USDC Judge Xinis to hold a likely contentious hearing in about six hours, now in Maryland, regarding Mr. Abrego-Garcia's future. Stay tuned, but there is no public audio feed. Onward.
नमस्ते
No comments:
Post a Comment